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Regulation of transepithelial ion transport and intracellular
calcium by extracellular ATP in human normal and cystic
fibrosis airway epithelium
S.J. Mason, A.M. Paradiso & R.C. Boucher
Department of Medicine, University of North Carolina Chapel Hill, North Carolina 27599, U.S.A.
1 The role of extracellular nucleotides in regulation of ion transport activities (short circuit current, Is¢)
of human respiratory epithelia was studied.
2 Application of nucleotides to the apical or basolateral membrane of human nasal epithelium induced a
concentration-dependent increase in IS..
3 The rank order of potency of purine- or pyrimidine-induced changes in ISC of normal human nasal
epithelium when applied to the apical membrane (UTP > ATP > ATPyS > 2MeSATP > ADPIIS >
PyMeATP > aq#MeATP) or basolateral membrane (2MeSATP > UTP > ATP > ATPyS > afiMeATP >
/JyMeATP) is consistent with involvement of a P2 purinoceptor. A similar rank order of potencies was
observed for nucleotide effects on intracellular calcium measured by Fura-2 fluorescence using micro-
spectrofluorimetry.
4 Similar nucleotide potency in the regulation of ion transport and intracellular calcium in cystic fibrosis
(CF) airway epithelium (UTP > ATP) was observed, suggesting purinoceptors might be used to stimulate
ion transport processes that would promote hydration of airway secretions and facilitate their clearance
from CF lungs.
5 These data provide evidence for the regulation of ion transport by P2 purinoceptors in normal and
cystic fibrosis human airway epithelium.
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nucleotide; pyrimidine nucleotide; calcium release
Introduction
Extracellular adenosine triphosphate (ATP) has been shown
to regulate a variety of biological processes including non-
vascular smooth muscle contraction (Maguire & Satchell,
1979; Brown & Burnstock, 1981) and vascular tone
(Burnstock & Kennedy, 1986; Haeussinger et al., 1987), plate-
let aggregation (Born & Kratzer, 1984), neurotransmission
(Burnstock, 1971; Burnstock & Sneddon, 1985), and cellular
ion transport (Burgess et al., 1979; Gallacher, 1982) and secre-
tory activities (Chapal & Loubatieres-Mariani, 1981; Pearson
et al., 1983). These effects are mediated by specific purinocep-
tors which respond to ATP or other nucleotides present in the
extracellular millieu (Gordon, 1986).
Purinoceptors have been functionally identified in rat pul-
monary epithelia in studies of regulation of alveolar Type II
surfactant phospholipid secretion (Rice & Singleton, 1986). To
our knowledge these receptors have not been described in
human airway epithelial cells. Because ion transport appears
to be regulated by purinoceptor stimulation in other eipthelia
(Burgess et al., 1979; Gallacher, 1982), we investigated several
features of the effect of extracellular nucleotides on the ion
transport activities of human airway epithelium.
Purinoceptor regulation of ion transport might have poten-
tial therapeutic benefit in lung diseases characterized by
abnormalities in epithelial ion transport, e.g., cystic fibrosis. In
cystic fibrosis (CF) the airway epithelial dysfunction is
expressed in part by defective regulation of Cl- ion transport
by secretagogues that regulate the apical cell membrane Cl-
channel by adenosine 3': 5'-cyclic monophosphate (cyclic
AMP)-dependent or protein kinase C-dependent mechanisms
(Boucher et al., 1986, 1989; Riordan et al., 1989; Rommens et
al., 1989). Induction of C1- secretion by CF airway epithelia in
vivo would be expected to help liquify the relatively dehy-
drated, thick airway surface liquid that characterizes this
disease. We therefore tested whether nucleotides would bypass
regulatory defects in CF airway epithelia and induce Cl
secretion at rates similar to those of normal airway cells. Con-
sequently, this study could suggest a new class of therapeutic
agents for the treatment of CF.
Methods
Cell culture
Freshly excised human nasal epithelium from normal or cystic
fibrosis subjects was grown in primary culture in F-12,
hormone-supplemented medium as previously described (Wu
et al., 1985). For [Ca2]i measurements, cultures were grown
on non-fluorescent vitrogen substrates on glass coverslips.
Cultures for electrophysiological studies were grown to con-
fluence on permeable collagen matrix supports (CMS), allow-
ing addition of agonists to the basolateral or apical surface of
the epithelial sheet.
Biolectric studies
Confluent monolayers of primary human nasal epithelium
were mounted in modified Ussing chambers (Knowles et al.,
1983; Boucher et al., 1988). The studies were performed under
short circuit current conditions at 37°C, and in some studies,
amiloride was added to the apical bath (1O-4 M) to block tran-
sepithelial sodium transport. Changes in transepithelial poten-
tial difference (VJ), resistance (R.) and short circuit current ('QJ)
were measured in response to addition of various nucleotides.
Each cultured preparation was exposed to only one concen-
tration of an agonist on either the basolateral or apical surface
to avoid the tachyphylaxis observed in preliminary cumulative
dose-response studies. To construct concentration-effect
relationships of responses to nucleotides, we assumed that the
same maximum response to an agonist could be induced from
each tissue culture preparation from the same individual (see
Statistics).
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Measurements of intracellular calcium
Primary human nasal epithelial cells grown to confluence on
vitrogen coated coverslips were loaded with a final concentra-
tion of 3 gM Fura-2/AM at 370C for 30 min. The cells were
then washed in NaCI Ringer and mounted in a chamber for
measurements of fluorescence. To reduce the rate of leakage of
Fura-2 from the cell into the extracellular space and avoid
time-dependent compartmentalization of the probe, all mea-
surements of [Ca2+]i were performed at 250C. At this tem-
perature, no vesicular bright spots indicative of
compartmentalization of the probe were observed.
Measurements of [Ca2+]i in single human nasal epithelial
cells were obtained with a modular microspectrofluorimeter
(SPEX Industries, Inc., Edison, NJ, U.S.A.) attached to a Zeiss
AxiovertIM 35 microscope. The system was equipped with a
xenon lamp, beam splitter, two monochromators and a rotat-
ing chopper mirror that permitted excitation of cell fluores-
cence at alternating wavelengths of 340 and 380 nm
(emission> 450 nm). The fluorescent signal from a single cell
was measured with a photometer equipped with a pinhole
(spot diameter of 3-5um) that excluded signals from adjacent
cells.
After agonist was added, the fluorescent signal was
quenched by a NaCl Ringer solution containing 1.5 x 10-'M
digitonin and 10-3M MnCl2. The remaining signal at each
excitation wavelength, equivalent to the background fluores-
cence in non-loaded cells, was subtracted from data from
Fura-2/AM loaded cells before the ratio (340nm/380nm) was
taken. The 340nm/380nm ratio was converted to an actual
[Ca2+]i measurement by using the external calibration stan-
dards and the formula derived by Grynkiewicz et al. (1985)
used with dual wavelength mcasurements: [Ca21]i = KI[(RX
- R.)/(R, - R.)], with R. and R, representing the ratios at 0
Ca2+ and saturating Ca2+, respectively. R, represents the
experimental ratio. K is Kd(FJFS), with Kd = 1.57 x 10- 7M at
25°C as the effective dissociation constant for Fura-2, and F0
and F. represent the fluorescence intensities at 380nm with 0
and saturating Ca2+, respectively.
Statistical methods
A relatively large variability in the maximal responses was
observed in tissues from different donors. However, the
responses (ISC or [Ca2+]i) within preparations from a single
donor were more homogeneous. To control for inter-donor
tissue variability, tissues from a single donor were used for the
entire concentration-range of a nucleotide agonist. Only
tissues with transepithelial potential difference greater than
-5 mV and transepithelial resistance greater than
100ohmscm2 were used in the studies. For comparing effec-
tiveness of ATP administered to the luminal versus basola-
teral surface of normal and CF preparations, the absolute
changes in IS, from basal levels are plotted. For comparison of
rank orders of potency for nucleotides, the percentage change
in ISC from basal levels is shown. For measurements of
[Ca21]i, only absolute changes from basal levels are plotted.
To estimate a representative variance for the response to
agonists, we (1), determined the absolute response to the
maximum agonist concentration; (2) calculated the percentage
of the maximal response yielded by each lower agonist con-
centration (normalized maximum percentage response); and
(3) calculated the variance of the normalized responses for
each agonist concentration in preparations from different
donors. Rank orders of potency of the agonists were obtained
by comparing EC50s of each agonist.
Chemicals and solutions
ATP, UTP, ATPyS, CTP, GTP, ITP, adenylyl-
imidodiphosphate (AMPPNP), fi,y-methylene ATP (fly-
MeATP), ADPflS, ADP, AMP, UDP, 5-BrUTP, UMP,
ATPaS and dipyridamole were obtained from Boehringer
Mannheim Biochemicals (Indianapolis, IN, U.S.A.). a,,8-
Methylene ATP (a,/i-MeATP) and amiloride were obtained
from Sigma Chemicals (St. Louis, MO, U.S.A.). 2-Methylthio
ATP (2MeSATP) was purchased from Research Biochemicals
Inc. (Natick, MA, U.S.A.).
Bioelectric properties were measured with confluent mono-
layers bathed by Ham's F-12 culture solution without
hormone supplements (Gibco, Grand Island, NY, U.S.A.).
The acetoxymethylester of Fura-2 (Fura-2/AM) and the
pentapotassium salt Fura-2 were purchased from Molecular
Probes (Eugene, OR, U.S.A.). To obtain external calibration
standards for the dye, the pentapotassium salt Fura-2 was
used at 15 fM in solution with 150mM KCl, 20mM NaCl,
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
(HEPES), and either 5mM CaCl2 or 2 mm EGTA.
For intracellular calcium studies, NaCI Ringer solution at
250C was employed, containing the following (in mM): NaCl
150, KCl 5, D-glucose 5, HEPES 10, CaCl2 2, MgCl2 2, ad-
justed to pH 7.4. For studies to determine the ionic form of
ATP active at the receptor, MgCl2 was varied in the above
NaCl Ringer between nominally Mg2 '-free, 2 mm and
5mM Mg2 . For studies with solutions free of calcium, 2mm
EGTA replaced the CaCl2.
Results
Normal human nasal epithelium-ion transport
The effects of extracellular ATP on normal human nasal epi-
thelium were investigated employing biolectric measurements
of ion transport activity when the nucleotide was applied to
either the apical or basolateral membrane. Representative
tracings obtained after application of ATP to cultured sheets
of human nasal epithelium mounted in Ussing chambers are
illustrated in Figure 1. Figure 1(a) and (b) represents the ISC
response when ATP is applied to the apical or basolateral
membrane of tissues in the basal, Na+ absorptive mode
(Boucher et al., 1986). ATP rapidly stimulated an increase in
ISC when applied to either surface. In general, the change in ISC
induced by application of ATP to the apical or the basolateral
side returned to baseline or below within 5min after addition
of agonist. Oscillations in ISC following ATP were frequently
observed. Apical pretreatment with amiloride (10-4M)
removes active Na+ absorption as a component of the I. so
that the residual ISC reflects a Cl- secretory current (Boucher
et al., 1986; Willumsen et al., 1989). Figure 1(c) and (d) rep-
resent the typical Cl- secretory response of human nasal epi-
thelium when ATP is applied to amiloride-pretreated tissues.
Following the initial peak, the ATP induced increase in ISC
after basolateral addition to amiloride-pretreated tissues
returned to baseline within 5min (Figure id). In contrast,
most tissues (91% of those followed for 10min) treated with
ATP on the apical surface following amiloride pretreatment
exhibited prolonged (> 10min) increases in ISC above baseline
levels (Figure ic).
The concentration-effect relationship of ATP applied to
normal human nasal epithelium under basal conditions is
shown in Figure 2. Comparisons were made between
responses of tissues from different donors based on the peak
change in IC following ATP application (see Figure 1). The
curve describes the mean peak change in Isc in response to
increasing log concentrations of ATP applied to the apical or
basolateral surface. The effectiveness of the nucleotide is
approximately equal when applied to the apical or basolateral
surface between 10-7 and 10-4M. A large increase in IC is
seen with IO- M ATP applied to the basolateral membrane
that is not seen with apical application.
Figure 3 illustrates concentration-effect relationships for
ATP applied to the apical or basolateral membrane of
amiloride-pretreated tissues. Again, the effect of ATP on ion
transport is shown as the mean peak change in IC after ATP
application. The change in ion transport induced by ATP in
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Figure 1 Representative tracings of effect on IJ, of extracellular ATP
(10-4M) applied to the apical or basolateral membrane of human
nasal epithelium. (a) Response of human nasal epithelium in basal
transport mode (primarily Na' absorptive) to ATP applied to the
apical surface (basal IC = 100 uAcm -2). (b) Response of human nasal
epithelium in basal mode to ATP applied to the basolateral surface
(basal IC = 94pA cm-2). (c) Cl - secretory response to ATP applied to
apical surface of amiloride-pretreated tissue (post-amiloride I, =
16puA cm-2). (d) CF- secretory response to ATP applied to the basola-
teral surface of amiloride-pretreated tissue (post-amiloride I =
6,1Acm 2).
amiloride-pretreated tissues is routinely smaller than that
observed in tissues in the basal state (Figure 2). The potency
and effectiveness of ATP in amiloride-treated tissues are
similar whether applied to the apical or basolateral membrane
and the log concentration-effect curves are sigmoidal in char-
acter, with EC50 values of approximately 1-2 x 10- 5 M.
The purinoceptor subtype(s) linked to regulation of ion
transport of human nasal epithelium were characterized by
obtaining concentration-effect relationships for a variety of
purine and pyrimidine agonists in preparations derived from
normal and CF patients. We characterized receptor subtype(s)
on the basolateral surface by measuring nucleotide effect on
basal Na' transport rates. Because therapies designed to
induce Cl- secretion might best be delivered by the aerosol
route, receptor subtype characterization on the apical barrier
was performed in the presence of amiloride. The effect of
extracellular nucleotides on ion transport is shown as the per-
centage change in I., from control values when applied to the
basolateral or apical surface of the culture. Basal pre-agonist
currents were similar for tissues in each concentration group
(see Figure legends).
Under the culture conditions employed in these studies, the
P1 receptor agonist adenosine, following preincubation of
tissues with dipyridamole (10-6M) to block adenosine uptake,
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Figure 2 Log concentration-effect relationship (mean change in I'S
from basal levels) of ATP applied to the apical (M) or basolateral (El)
surface of human nasal epithelium without amiloride-pretreatment.
Mean ISC of tissues in basal mode for range of ATP concentrations
tested were (in 1uAcm-2): apical ATP 80 + 2, range 16-150, n = 3-9
at each agonist concentration; basolateral ATP 68 + 5, range 17-138,
n = 3-13 at each agonist concentration. S.e.mean of each data point is
< 12% of the normalized maximum response.
ATP (compare with Figures 4 and 5, below). Addition of
adenosine to the apical surface of amiloride-pretreated human
nasal epithelium at 10 -5M (n = 7) or 1O-4M (n = 8) induced
an increase of 10 + 7 or 10 + 6%, respectively, whereas addi-
tion of the same doses to the basolateral barrier (n = 8, each
dose) raised I., by less than 5%. These findings suggest that
the activation of P1 receptors contributes little to the mea-
sured effects of extracellularly applied ATP on ion transport.
Therefore, we focused on agonists that interact with P2 recep-
tors in the regulation of ion transport and [Ca2+]i mobi-
lization in human nasal epithelium.
Figure 4 illustrates the concentration-effect relationships of
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Figure 3 Log concentration-effect relationships (mean change in I.
over basal levels) of ATP applied to the apical (-) or basolateral (El)
membrane of amiloride-pretreated (10-4M) human nasal epithelium.
Mean ISC of amiloride-pretreated tissues for the range of ATP concen-
trations tested were (in puA cm-2): apical ATP, 13 ± 1, range 9-16,
n = 3-11 at each agonist concentration; basolateral ATP, 14 ± 1,
range 8-28, n= 3-6 at each agonist concentration. S.e.mean of each
data point is < 12% of the normalized maximum response.
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Figure 4 Log concentration-effect curves (percentage change in I,,
from basal levels) of nucleotides applied to the basolateral surface of
normal human nasal epithelium. Mean basal I., in each set of experi-
ments were (in pAcm-'): ATP (0), 69 + 5, range 55-80, n = 5
(n = 3-11 at each agonist concentration); UTP (0), 66 ± 9, range
21-158, n = 9 (n = 3-23); 2MeSATP (EJ), 48 ± 6, range 35-65, n = 6
(n = 3-17); ATPyS (U), 47 + 8, range 28-72, n = 3 (n = 3); ADP,6S
(A), 49 + 6, range 36-65, n = 3 (n = 3); 4iMeATP ('Z), 51 + 12,
range 28-66, n = 3 (n = 3); flyMeATP (A), 79 + 21, range 59-100,
n = 3 (n = 3). S.e.mean of each data point is < 15% of the normalized
maximum response.
lium. Compared to the concentration-effect curve of ATP,
agonists that stimulate P2. receptors (qxfMeATP and
flyMeATP) induced little change in ion transport rates. The
observed rank order of potency for agonists that significantly
increased ISC was 2MeSATP > UTP > ATP >
ATPys > ADP > ADPfS. At concentrations of ATP, UTP,
ATPyS or ADPfiS between lo-7 and 10-4M, the relationship
between log agonist concentration and observed responses
was a curve of sigmoidal character. The concentration-effect
curve of these agonists was biphasic in character when the
effect on I.C of 10 3M drug was considered.
The concentration-effect relationships for nucleotides added
to the apical surface of amiloride-pretreated tissues are shown
in Figure 5. Compounds reported to be effective P2X receptor
agonists produced little change in ion transport by airway epi-
thelium. Those reported to be effective P2y or UTP-sensitive
receptor agonists stimulated Cl- secretion with the following
rank order of potency: ATP > UTP > ATPyS >
ADP > 2MeSATP > ADPflS.
In an attempt to test whether multiple P2 receptor types are
expressed on each membrane, or a single novel receptor
subtype is expressed on either barrier, additivity studies were
performed using two ligands that supposedly interact with
separate receptor subtypes, UTP and 2MeSATP. Co-addition
of saturating concentrations of 2MeSATP (10-kM) and UTP
(10-4M) on the basolateral membrane induced an effect that
was about twice that induced by each of the agonists alone in
sets of tissue preparations obtained from three separate
donors. The mean increase in ISC for UTP alone was
4.6 + 0.5 pA cm2, and for 2MeSATP alone was
4.3 + 0.9 uA cm- 2, whereas current increased 10 + 1 uA cm-2
in response to the combination of UTP and 2MeSATP
(n = 3). The additivity observed suggests each ligand interacts
with a separate receptor on the basolateral membrane. When
the two agonists were applied to the apical surface singly and
in combination following amiloride, no additive effects were
evident.
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Figure 5 Log concentration-effect curves (percentage change in I,
from basal levels) of nucleotides applied to the apical surface of
human nasal epithelium pretreated with amiloride (10-4M). Mean
post-amiloride ISc in each set of experiments were (in pAcm- 2): ATP
(0), 13 + 1, range 9-16, n = 8 (n = 3-11 at each agonist
concentration); UTP (@), 12 ± 1, range 11-15, n = 5 (n = 3-17);
ATPyS (-), 12 + 1, range 8-15, n = 3 (n = 3); 2MeSATP (l), 16 + 2,
range 12-21, n = 3; (n = 3-7); ADPflS (A), 15 + 1, range 13-16, n = 3
(n = 3) fiyMeATP (A), 14 + 0, range 8-19, n = 3 (n = 3); afMeATP
(c), 11 + 0, range 7-14, n = 3 (n = 3). S.e.mean of each data point is
< 13% of the normalized maximum response.
Normal human nasal epithelium-intracellular calcium
Based on studies in other epithelia indicating that regulation
of [Ca2+]i by purinoceptors initiates changes in ion transport
rates (Kimmich & Randles, 1982), we investigated whether
ATP regulated [Ca2+]i in single human nasal epithelial cells
using an intracellular Ca2+-sensitive fluorescent dye. Extra-
cellular application of ATP induced an immediate increase in
[Ca2+]i levels that decreased over 1 to 2min to a prolonged
plateau (Figure 6a). Exposure to ATP in Ca2+-free medium
resulted in an initial sharp increase in [Ca2+]i which returned
to baseline over a 2 min period with no plateau phase
observed (Figure 6b). Return of the cells to a Ca2 -containing
solution resulted in restoration of the plateau phase in the
Ca2 + response to ATP.
To investigate whether changes in [Ca2+]i might be related
to regulation of ion transport, receptor characterization was
performed by measuring changes in [Ca2+]i in response to a
number of nucleotide drugs. Concentration-effect curves for
angonists active at P2.1 P2y subtype or UTP-sensitive recep-
tors and other purine or pyrimidine receptor agonists were
generated, measuring mean change in [Ca21]i in response to
agonist concentration (Figure 7). ATP, UTP and ATPyS were
the most effective agonists. Classical P21 (4,?MeATP and
flyMeATP) and P2Y (2MeSATP and ADPIIS) receptor agon-
ists had little effect (Figure 7a) as did other analogues of ATP
and ADP (Figure 7b). 5BrUTP was essentially as effective as
UTP for stimulation of Ca2 + mobilization (Figure 7c).
To characterize the chemical form of ATP interacting with
the purinoceptor on human nasal epithelium, fluorescence
measurements of single cell [Ca2+]i response to ATP (10-3 to
10-8M) were obtained with various levels of Mg2+ in the
extracellular medium. Increasing [Mg2+] resulted in a shift to
the right of the dose-response curve: the EC50 values for ATP
were 5 x 10-6M in solutions nominally Mg2+-free;
2 x 10- M in solutions containing 2mmMg2+; and
1 x 1O-4M in solutions containing 5mMMg2+ (n = 4 for each
Mg2+ concentration). These shifts suggest that the free acid
form ATP4- is the active form at human airway P2 receptors
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Figure 6 The effect of ATP (10-4M) on the concentration of intracel-
lular calcium [Ca2+]i in single human nasal epithelial cells with (a)
and without (b) 2mM Ca2" in the bathing medium. In (b) external
Ca2+ was restored to the culture medium after the peak response to
ATP, resulting in a plateau level above baseline. The increase in
[Ca2 ]i is calculated from the change in fluorescence due to increased
binding of free Ca2" by the dye Fura-2 (30min preincubation with
culture at 370C at 3 FM concentration). (a) and (b) are representative of
9 experiments performed on separate tissues from 8 patients. Mean
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rather than MgATP2-, the ionic form more prevalent under
most physiological conditions. The EC50 value of bradykinin,
another agent which increases [Ca2+]i in human nasal epithe-
lial cells via a non-purinoceptor (Paradiso et al., 1989), was
not altered by varying [Mg2"] in the extracellular medium.
Cystic fibrosis nasal epithelium
Availability of CF tissues is limited, and our investigation of
effects of nucleotides was restricted to examining regulation of
Cl- secretion rates and [Ca2+]i levels by ATP and UTP.
Only small changes in Cl- secretion (amiloride-resistant IJ,)
were observed in CF tissues following basolateral addition of
ATP (14 + 3 maximum mean % change in Ise, n = 6) com-
pared with normal tissues (51 + 8 maximum mean % change
in Is, n = 6). Apical administration of ATP following block-
ade of Na+ absorption with amiloride resulted in two distinct
patterns of response in tissues from CF subjects (Figures 8
and 9). Most tissues exhibited an increase in I,, over basal
levels after ATP (Figure 8a), suggesting stimulation of Cl-
secretion. However, approximately 30% of CF tissues tested
responded with a change to opposite polarity of Ik, following
ATP (Figure 8b), suggesting a secretion dominated by cations
in these preparations (Bean & Friel, 1990). UTP applied to the
apical surface routinely stimulated increases in Cl- secretion
in CF tissues (Figure 8c). Mean peak change in ISC from post-
amiloride basal levels in response to ATP or UTP application
was measured in individual CF tissues to obtain the
concentration-effect relationships illustrated in Figure 9.
Increases in [Ca2'+] in CF tissues were also observed after
addition of ATP or UTP (Figure 10). The similar potency and
effectiveness of ATP and UTP in these tissues suggests the
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Figure 7 Log concentration-effect relationships of purine and pyrim-
idine compounds on [Ca2+]i (mean change in [Ca2+]J over basal
levels). (a) comparison of agonists which bind to P2., P2y or UTP-
sensitive receptors, mean basal [Ca21]i in each set of experiments
were (in nm): UTP (O), 81 + 8, range 48-113, n = 5 (n = 3-6 at each
agonist concentraion); ATPyS (-), 116 + 11, range 85-151, n = 4
(n = 3-6); ATP (El), 61 + 3, range 51-70, n = 8 (n = 3-8); 2MeSATP
(-), 123 + 19, range 95-180, n = 3 (n = 3); ADP,/S (A), 91 + 17,
range 74-107, n = 3 (n = 3); ocIIMeATP (K>), 82 + 16, range 50-99,
n = 3 (n = 3); jyMeATP (A), 68 + 4, range 61-74, n = 3 (n = 3). (b)
Comparison of other purine agonists with response stimulated by
ATP (0). Mean basal [Ca2+]i in each set of experiments were (nM):
GTP (0), 117 + 13, range 92-153, n = 3 (n = 3); AMPPNP (l),
137 + 50, range 74-235, n = 3 (n = 3); ITP (-), 103 + 10, range
85-121, n = 3 (n = 3); ADP (A), 94 + 16, range 75-127, n = 3 (n = 2-
3); AMP (A), 111 ±.28, range 69-189, n = 3 (n = 3); ATPaS (O),
89 + 2, range 87-91, n = 1 (n = 2). (c) Comparison of UTP (0) with
other pyrimidine agonists, mean basal [Ca2+]i (in nM): 5BrUTP (0),
110 ± 13, range 82-152, n = 3 (n = 2-3); UDP (El), 89 ± 2, range
84-92, n = 3 (n = 3); CTP (A), 83 10, range 69-102, n = 3 (n = 3);
UMP (U), 78 14, range 64-91, n = 2 (n = 2). S.e.mean of each data
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Figure 8 Representative bioelectric tracings of effect on Iw of extra-
cellular ATP (10-4M) or UTP (10-'M) applied to the apical surface of
amiloride-pretreated (10-4M) CF human nasal epithelium. (a) Cl-
secretion in response to ATP (post-amiloride I,, = 134uAcm - 2). (b) I
response to ATP of opposite polarity (post-amiloride IM =
l9pAcm-2). (c) Cl secretory response to UTP (post-amiloride I =
5pA cm-2).
Discussion
We have demonstrated that ATP modulates ion transport
rates when added to either the apical or basolateral surface of
human airway epithelium. These effects appear to be mediated
by cell surface receptors that respond to ATP by regulating
ion transport rates, which may be related to release of Ca2+
from internal stores and extracellular Ca2 + influx.
The ion transport activities measured in this study are
believed to be important in regulation of the volume and com-
position of secretions produced by human airway cells
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Figure 9 Log concentration-effect curves for changes in I, from
basal levels when ATP or UTP are applied to the apical surface of
amiloride-pretreated (10-M) cystic fibrosis tissues. Mean post-
amiloride ISC in each set of experiments were (in pAcm 2): ATP
[Group A (-), Group B (El)], 13 ± 1, range 3-31, n = 4 (n = 4-13 at
each agonist concentration); UTP (0), 12 ± 2, range 8-14, n = 3
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Figure 10 Log concentration-effect relationships of the effect of ATP
and UTP on [Ca2+]i (change from basal levels) in single cystic fibro-
sis nasal epithelial cells. Mean basal [Ca+]i (in nM): ATP (O),
65 ± 6, range 44-86, n = 3 (n = 3 at each agonist concentration);
UTP (0), 67 + 3, range 56-79, n = 3 (n = 3-4). S.e.mean of each data
point is <, 8% of the normalized maximum response.
kinin and histamine probably alter the water content of
luminal secretions through their effects on ion flow and thus
affect the rate of clearance of these secretions within the
airways. Our characterization of the effects of nucleotide
receptors on human nasal epithelial transport rates has led to
insights into the functional effects of activation of these recep-
tors on the metabolism of airway secretions. For example,
ATP applied to the basolateral surface of the epithelium
induces a large increase in ion transport rate (ISC reflecting a
component of increased absorption of Na+ in response to
ATP. The increase in Na+ absorption results in increased
water movement across the epithelium, likely acting to deplete
the volume of airway surface liquid. Amiloride blocks Na+
absorption and stimulates C1- secretion in human nasal epi-
thelium, probably reversing the direction of water flow. Con-
sequently, addition of ATP to the luminal surface of the
epithelium during amiloride treatment would probably accel-
erate this rate of Cl- secretion and water movement.
Our ion transport data suggest the presence of at least one
of the several reported P2 receptor subtypes (Burnstock &
Kennedy, 1985) on both the apical and basolateral membrane.
The receptor on either membrane that initiates the ion trans-
port responses is clearly not of the P2X subtype as basal ISC
shows little or no change in response to the potent P2X agon-
ists q,8MeATP and #yMeATP. The rank orders of potency
and efficacy for agonists applied to the apical surface of
human nasal epithelium were: ATP >, UTP > ATPyS >
2MeSATP > ADPBS. This relationship is suggestive of the
presence of a receptor sensitive to UTP and not of the typical
P2V subtype, which interacts most potently, with 2MeSATP
and ADPBS. A putative P2 receptor responding wvith approx-
imately equal potency to UTP and ATP has been reported in
a number of cell types, including human neutrophils (Seifert et
al., 1989; Cockcroft & Stutchfield, 1989; Kuroki & Minakami,
1989), HL60 cells (Cockcroft & Stutchfield, 1989), fibroblasts
(Fine et al., 1989), amnion cells (Vander Kooy et al., 1989),
Ehrlich ascites tumour cells (Dubyak & De Young, 1985),
pituitary cells (Davidson et al., 1990), A431 epidermoid carcin-
oma cells (Hosoi & Edidin, 1989), J774 mouse macrophage
cells (Greenberg et al., 1988) and perfused rat liver
(Haeussinger et al., 1988). Controversy exists at present about
whetherUT
separate pyrimidine receptor (Haeussinger et al., 1987; von
Kuegelgen et al., 1987; Seifert & Schultz, 1989; Stutchfield &
Cockcroft, 1990; Pfeilschifter, 1990).
Rank orders of potency of nucleotides added to the basola-
teral membrane suggest that the P2 receptor(s) found there are
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also not of the P2. or P2y subtype, and are sensitive to UTP.
The ISC rank order of potency (2MeSATP >
UTP > ATP > ATPyS > ADPflS) for nucleotide additions to
the basolateral membrane does raise the possibility that two
receptor subtypes may be required to account for the
observed functional responses. The potency of the prototype
P2Y receptor agonist, 2MeSATP, was greater than that of the
other agonists tested. However, the lack of effect of another
classical P2Y agonist, ADP/8S, compared to 2MeSATP in
human nasal epithelium makes it unlikely that the receptor
mediating ISc response is the usual P2Y receptor subtype. No
currently accepted P2 receptor subtype fits this potency
profile. Additive studies with 2MeSATP and UTP suggest
that two receptor subtypes rather than a single receptor may
be required to account for this profile. Similar studies on the
apical membrane did not suggest the presence of two receptor
subtypes, but the failure to detect additivity could reflect limi-
tations of the maximal response measured in this assay (Cl-
secretion), as compared to that of basolateral addition (Na'
absorption). Rigorous identification of the presence of more
than one P2 receptor subtype on either membrane of human
nasal epithelium will require antagonist compounds not cur-
rently available.
The concentration-effect relationship of potent agonists
added to the basolateral membrane was biphasic in character
when the ISC response to 10 3M drug is considered (Figure 4).
However, in experiments in which ATP was added to the
basolateral surface in the presence of amiloride, the relation-
ship was sigmoidal (Figure 3), suggesting that a process that
regulates the rate of Na. absorption is responsible for the
large increment of IM at millimolar drug concentrations.
Because increased Na+ absorption is probably the transport
process that contributes to the change in I,, at lower nucleo-
tide concentrations, the biphasic response may indicate
linkage of purinoceptors to two effector systems that regulate
Na+ transport rates.
As in the ISC studies, changes in cell [Ca2+]i induced by
nucleotides cannot be explained by a P2 receptor of the P2X
subtype. Rank orders of potency of agonists
(UTP > ATP > ATPyS > 2MeSATP > ADPfiS) suggest the
presence of a UTP-sensitive receptor. Sensitivity of this recep-
tor to the presence of Mg2+ ions suggests that it is activated
by the free acid form ATP-. It is not possible to speculate
about the nature of receptors on the apical and basolateral
membranes because agonists may have access to both sides of
cells grown on coverslips. Ongoing studies of polarized epithe-
lial preparations specially configured for fluorescent [Ca2+]i
measurements should help to elucidate the receptor type(s)
present on each membrane.
The ion transport and [Ca2+]i data suggest that human
airway epithelium responds to various extracellular nucleo-
tides via a receptor-mediated mechanism. By analogy to other
epithelia, this mechanism probably involves phospholipase C-
mediated breakdown of membrane phospholipids to inositol
phosphates, coupled with release of Ca2 + from internal stores.
Preliminary studies in normal primary human nasal epithe-
lium and CF cell lines in which inositol phosphate production
in response to nucleotides was measured, support phospho-
lipid breakdown as the mediator of calcium release (H. Alex
Brown, personal communication). The similar EC50s for the
ISC response and Ca2+ response to various nucleotide agonists
also support a link between these two phenomena.
The effectiveness of extracellular nucleotides in stimulating
Cl- secretion by amiloride-pretreated normal human airway
epithelium raises the question of therapeutic uses for these
compounds in diseases of epithelial dysfunction like cystic
fibrosis. Although regulatory pathways that involve cyclic
AMP and Ca2+ phospholipid-dependent protein kinases are
defective in CF airway epithelium (Boucher et al., 1986), a
recent report indicates that Ca2+-dependent Cl- secretory
regulatory mechanisms are retained by CF epithelia (Boucher
et al., 1989). Our data show [Ca21]i was increased and CP-
secretion stimulated by ATP and UTP in CF airway epithelial
cells pretreated with amiloride. In a recent pilot study, amilo-
ride administered by the aerosol route was reported to slow
but not abolish the progression of CF lung disease (Knowles
et al., 1990). The mode of action is probably via a reduction of
the excessive rate of Na' absorption that also characterizes
this disease and, consequently, conservation of liquid on the
airway surface. ATP or UTP combined with amiloride and
administered to target the airway epithelium might act to
induce Cl- secretion toward the airway lumen, further
increasing the water content of secretions and increasing their
rate of clearance from the respiratory system. Thus, by com-
bining purinoceptor agonists as a new class of therapeutic
agents with amiloride, it may be possible to abolish the loss of
lung function consequent to this disease.
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